Rezpegaldesleukin not checked
Nektar Therapeutics · NKTR-358 · LY3471851
FollowEvery change as it happens, and a Monday email
Trials
3 active
13 in total · 4 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Pharmaceutical form: Injection solution Route of administration: subcutaneous”In the company’s words, NCT07690371 on ClinicalTrials.gov
- Tested for
- Moderate-to-Severe Atopic Dermatitis (2 trials), Moderate to Severe Atopic Dermatitis
- Main trialPhase 3
- “This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approximately 15 months.”In the company’s words, NCT07690371 on ClinicalTrials.gov
- Other names
- REZPEG · NKTR-358 · LY3471851
Other drugs for Moderate-to-Severe Atopic Dermatitis
- ICP-332Beijing InnoCare Pharma Tech Co., Ltd. · Phase 3
- UpadacitinibAbbVie · Phase 3
- DifamilastOtsuka Pharmaceutical Co., Ltd. · Phase 3
- MG-K10Shanghai Mabgeek Biotech.Co.Ltd · Phase 3
- GX-03Turn Therapeutics · Phase 2/3
- VC005Jiangsu vcare pharmaceutical technology co., LTD · Phase 3
Coming up2
- May 2028Phase 3 trial completes · ClinicalTrials.gov
- Jun 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | May 2028 | A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis | |
| Phase 3Recruiting | Jun 2028 | A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis | |
| Phase 2Active, not recruiting | 6 May 2025 | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis | |
| Phase 2Terminated | 9 Aug 2022 | A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) | |
| Phase 2Completed | 10 Jan 2023 | A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) | |
| Phase 2Completed | 26 Nov 2025 | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) | |
| Phase 1Completed | 20 Jan 2019 | A Study of NKTR-358 (LY3471851) in Healthy Participants | |
| Phase 1Completed | 29 Aug 2019 | A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE) | |
| Phase 1Completed | 6 Mar 2020 | A Study of LY3471851 in Healthy Participants | |
| Phase 1Completed | 21 Jul 2021 | A Study of LY3471851 in Participants With Psoriasis | |
| Phase 1Completed | 24 Jun 2022 | A Study of LY3471851 in Participants With Eczema | |
| Phase 1Completed | 6 Jul 2022 | A Single-Dose Study of LY3471851 in Healthy Participants | |
| Phase 1Completed | 23 Feb 2023 | A Phase I Study of LY3471851 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026